This cross-sectional observational case-control study aimed to examined serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study also aimed to assessed systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examined associations between biomarkers and clinical symptom severity, including Insight Assessment Scale (IAS) and Positive and Negative Syndrome Scale (PANSS) scores.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5)
Timeframe: At hospital admission (baseline)
Olfactomedin-4 (OLFM4)
Timeframe: At hospital admission (baseline)
Mehmet Hamdi ÖRÜM, MD, Assoc. Prof., Psychiatrist